Preview

Опухоли женской репродуктивной системы

Расширенный поиск

ДИАГНОСТИКА И ПРОФИЛАКТИКА КАРДИОТОКСИЧНОСТИ У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ С ПОЗИЦИЙ ОНКОЛОГА И КАРДИОЛОГА

https://doi.org/10.17650/1994-4098-2017-13-3-17-27

Полный текст:

Аннотация

Знание патогенеза и основных факторов риска кардиотоксичности антрациклиновыми антибиотиками (АА) позволило разработать различные методики, направленные на предупреждение и раннее выявление кардиотоксичности, а также создать ряд рекомендаций по уменьшению риска ее развития. Традиционные АА являются важнейшей опцией лечения метастатического рака молочной железы, включая повторное их назначение. Однако возможности их применения значительно ограничены из-за различных проявлений токсичности, особенно кумулятивной кардиотоксичности. Наиболее перспективным является применение пегилированных липосомных лекарственных форм АА. И в их ряду пегилированный липосомальный доксорубицин благодаря своей уникальной формуле практически не обладает антрациклиновой кардиотоксичностью, так как накапливается преимущественно в опухолевой ткани.

Об авторах

Т. Ю. Семиглазова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВО «Cеверо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия

Татьяна Юрьевна Семиглазова.

197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 191015, Санкт-Петербург, ул. Кирочная, 41



Г. М. Телетаева
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России
Россия

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68



Н. А. Козявин
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России
Россия

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68



А. В. Загатина
ООО «Клиника “Медика”»
Россия

191144, Санкт-Петербург, ул. Дегтярная, 23/25 лит. А, помещение 8Н



Список литературы

1. Стуков А.Н., Бланк М.А. , Семиглазова Т.Ю. и др. Фармакотерапия опухолей (Посвящается памяти Михаила Лазаревича Гершановича). Под ред. А.Н. Стукова, М.А. Бланка, Т.Ю. Семиглазовой, А.М. Беляева. СПб: Вопросы онкологии, 2017. С. 238–69. [Stukov A.N., Blanc M.A., Semiglazova T.Y. et al. Pharmacotherapy of tumors (Dedicated to the memory of Mikhail Lazarevich of Gershanovich). Eds. A.N. Stukov, M.A. Blanc, T.Y. Semiglazova, A.M. Belyaev. SPb: Voprosy onkologii, 2017. Р. 238–69. (In Russ.)].

2. Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and ship statistics, survi-vor 2012. CA Cancer J Clin 2012;62(4):220–41. DOI: 10.3322/caac.21149. PMID: 22700443. PMID: 23485231.

3. Овчинников А.Г., Скоробогатова А.В., Семиглазова Т.Ю., Козявин Н.А. и др. Кардиотоксическое действие трастузумаба: механизмы развития, диагностика, лечение. Вопросы онкологии 2016;6: 719–31. [Ovchinnikov A.G., Skorobogatova A.V., Semiglazova T.U., Kozyavin N.A. et al. Cardiotoxicity trastuzumab: mechanisms of development, diagnosis, treatment. Voprosy onkologii = Problems in Oncology 2016;6:719–31. (In Russ.)].

4. Armstrong G.T., Oeffinger K.C., Chen Y. et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673–80. DOI: 10.1200/JCO.2013.49.3205. PMID: 24002505.

5. Zamorano J. L., Lancellotti P., Rodriguez Munoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768–801. DOI: 10.1093/eurheartj/ehw211. PMID: 27567406.

6. Riccio G., Coppola C., Piscopo G. et al. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Hum Vaccin Immunother 2016;12:1124–31. DOI: 10.1080/21645515.2015.1125056. PMID: 26836985.

7. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–79. DOI: 10.1002/cncr.11407. PMID: 12767102.

8. Mantarro S., Rossi M., Bonifazi M. et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123. DOI: 10.1007/s11739-015-1362-x. PMID: 26712595.

9. Lancellotti P., Galderisi M., Donal E. et al. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Failure 2017;4:312–8. DOI: 10.1002/ehf2.12162. PMID: 28772051.

10. Chow E.J., Chen Y., Kremer L.C. et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 2015;33:394–402. DOI: 10.1200/JCO.2014.56.1373. PMID: 25287823.

11. Ezaz G., Long J.B., Gross C.P. et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014;3:e000472. DOI: 10.1161/JAHA.113.000472. PMID: 24584736.

12. Thavendiranathan P., Grant A.D., Negishi T. et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77–84. DOI: 10.1016/j.jacc.2012.09.035. PMID: 23199515.

13. Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1–39. DOI: 10.1016/j.echo.2014.10.003. PMID: 25559473.

14. Plana J.C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063–93. DOI: 10.1093/ehjci/jeu192. PMID: 25239940.

15. Cardinale D., Colombo A., Lamantia G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–20. DOI: 10.1016/j.jacc.2009.03.095. PMID: 20117401.

16. Negishi K., Negishi T., Hare J.L. et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493–8. DOI: 10.1016/j.echo.2013.02.008. PMID: 23562088.

17. Voigt J.U., Pedrizzetti G., Lysyansky P. et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ ASE/ Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 2015;16:1–11. DOI: 10.1093/ehjci/jeu184. PMID: 25525063.

18. Jolly M.-P., Jordan J.H., Meléndez G.C. et al. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J of Cardiovas Magnetic Resonance 2017. DOI: 10.1186/s12968-017-0373-3. PMID: 28768517.

19. Srikanthan K., Klug R., Tirona M. et al. Creating a biomarker panel for early detection of chemotherapy related cardiac dysfunction in breast cancer patients. J Clin Exp Cardiolog 2017;8(3):pii: 507. DOI: 10.4172/2155-9880.1000507. PMID: 28642833.

20. Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121–129. DOI: 10.1016/j.pcad.2010.04.002. PMID: 20728699.

21. Ky B., Carver J.R. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. Heart Fail Clin 2011;7:323–31. DOI: 10.1016/j.hfc.2011.03.00. PMID: 21749884.

22. Wittayanukorn S., Qian J., Westrick S.C. et al. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or β-blockers in older adults with breast cancer. Am J Clin Oncol 2017; May 23. Publish Ahead of Print. DOI: 10.1097/COC.0000000000000389. PMID: 28537988.

23. Gulati G., Heck S.L., Ree A.H. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebocontrolled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671–80. DOI: 10.1093/eurheartj/ehw022. PMID: 26903532.

24. Pituskin E., Haykowsky M., Mackey J.R. et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101–Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011;11:318. DOI: 10.1186/1471-2407-11-318. PMID: 21794114.

25. Guglin M., Munster P., Fink A.et al. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am Heart J 2017;188:87–92. DOI: 10.1093/ehjci/jeu184. PMID: 25525063.

26. Floyd J.D., Perry M.C. Cardiotoxicity of cancer therapy. Chapter 19. In: The chemotherapy source book. Ed. Perry M.C. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:179–91.

27. Schimmel K., Richel D.J., Renee B.A. et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181–91. DOI: 10.1016/j.ctrv.2003.07.003. PMID: 15023436.

28. Jones R., Ewer M. Cardiac and cardiovascular toxicity of non-anthracycline drugs. Expert Rev Anticancer Ther 2006;6:1249–69. DOI: 10.1586/14737140.6.9.1249. PMID: 17020459.

29. Yeh E., Bickford C. Cardiovascular complications of cancer therapy incidence pathogenesis diagnosis and management. J Am College of Cardiology 2009;53:2231–47. DOI: 10.1016/j.jacc.2009.02.050. PMID: 19520246.

30. Ewer M., Benjamin R.S. Cardiotoxicity of chemotherapeutic drugs. In: The chemotherapy source book. Ed. Perry M.C. 3d ed. Philadelphia: Lippincott Williams&Wilkins 2001:458–68.

31. Floyd J.D., Perry M.C. Cardiotoxicity of cancer therapy. Chapter 19. In: The chemotherapy source book. Ed. Perry M.C. 4th ed. Philadelphia: Lippincott Williams &Wilkins 2008:179–91.

32. Crone S.A., Zhao Y.Y., Fan L. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8(5):459–65. DOI: 10.1038/nm0502-459. PMID: 11984589.

33. Symon Z., Peyser A., Tzemach D. et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999;86:72–8. PMID: 10391566.

34. O’Brein M.E., Wigler N., Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–9. PMID: 4998846.

35. Keller A.M., Mennel R.G., Georgoulias V.A. et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mytomycin C plus vinblastin in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22(19):3893–901. DOI: 10.1200/JCO.2004.08.157. PMID: 15459210.

36. Woll P.J., J. Carmichael, A.H. Calvert et al. Doxil plus paclitaxel in patients with metastatic breast cancer: update of phase II efficacy and safety study. ASCO 2001;20:67b.

37. Gasparini G., Morabito A., Fanelli M. et al. Phase I–II study of liposomal doxorubicin and docetaxel as first-line treatment in in patients with metastatic breast cancer. ASCO 2002; 21:54b.

38. Moore M.R., Srinivasian J.et al. Phase III randomized trial of doxorubicine plus paclitaxel (AT) versus doxorubicine HCI liposposome injection plus paclitaxel (DT) in metastatic breast cancer. ASCO 1998; аbstr.614.

39. Jones V., Finucane D. et al. Phase II study of weekly paclitaxel and liposomal doxorubicin in patients with locally advanced and metastatic breast cancer. ASCO 2000;19:116а.

40. Chia S.K., Clemons M., Martin L.A. et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24(18): 2773–8. DOI: 10.1200/JCO.2005.03.8331. PMID: 16682726.

41. Wolff A.C., Wang M. et al. Cardiac safety and clinical activity of pegylated liposomal doxorubicin and docetaxel with and without trastuzumab as 1st line chemotherapy in HER-2 positive and HER-2-negative metastatic breast cancer. 27th Annual San Antonio Breast Cancer Symposium 2004; abstr. 3040.

42. Wolff A.C., Wang M., Li H. et al. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 2010;121(1):111–20. DOI: 10.1007/s10549-010-0838-7. PMID: 20333545.

43. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92. DOI: 10.1056/NEJM200103153441101. PMID: 11248153.

44. Martin M., Sánchez-Rovira P., Muños M. et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 2011;22(12):2591–6. DOI: 10.1093/annonc/mdr024. PMID: 21421542.


Для цитирования:


Семиглазова Т.Ю., Телетаева Г.М., Козявин Н.А., Загатина А.В. ДИАГНОСТИКА И ПРОФИЛАКТИКА КАРДИОТОКСИЧНОСТИ У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ С ПОЗИЦИЙ ОНКОЛОГА И КАРДИОЛОГА. Опухоли женской репродуктивной системы. 2017;13(3):17-27. https://doi.org/10.17650/1994-4098-2017-13-3-17-27

For citation:


Semiglazova T.Y., Teletaeva G.M., Kozyavin N.A., Zagatina A.V. DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST. Tumors of female reproductive system. 2017;13(3):17-27. (In Russ.) https://doi.org/10.17650/1994-4098-2017-13-3-17-27

Просмотров: 172


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)